The business operates a facility in Limoges (France), recognised for its advanced botanical extraction and high-end manufacturing capabilities. Its ingredients and diagnostic solutions are commercialised worldwide and used by leading brands across both sectors.
This acquisition represents a strategic opportunity for Solabia to reinforce its global position as a leading supplier of high performance substantiated botanical active ingredients for cosmetics applications, while also securing a critical raw material supply for its diagnostics activities. By combining forces, the Group will accelerate the development of innovative solutions across both the cosmetics and diagnostics markets, two sectors in which Solabia is already strongly active and committed to long-term growth.
Jean-Baptiste Dellon, CEO of Solabia, commented:
“We are pleased to welcome the SEQENS Botanical Actives and IVD teams into Solabia. Because we operate in the same core activities, this acquisition is a natural and highly complementary fit. By combining our capabilities, we will reinforce our market position, secure critical supply chains, and offer our clients more robust and innovative solutions. This acquisition fully supports our development strategy as we continue to strengthen our business in markets with strong growth potential.”
Pascal Villemagne, CEO of SEQENS, declared:
“This transaction is fully consistent with our long-term strategic vision. It enables SEQENS to further focus on its core priorities, while ensuring that the Limoges teams join a group whose industrial culture, scientific expertise and growth ambitions are strongly aligned with their activities. We are confident that this new chapter with Solabia offers a robust and sustainable platform for the continued development of the site, its people and its know-how.”
For more information, please contact:
Emmanuelle Morillon - Communication Manager
Emmanuelle.morillon@solabia.fr